Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07236190). This is a study registration, not published results. Lead sponsor: Massachusetts General Hospital. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 40 participants (ESTIMATED). Conditions: Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD). Interventions: COMBINATION_PRODUCT: natural product combination-1 (NPC1). Primary outcome measures: plasma p-tau217 , 6 months; plasma glial fibrillary acidic protein , 6 months; plasma neurofilament light chain , 6 months; plasma abeta42 / abeta40 , 6 months; Safety and Tolerability of NPC1 , Baseline through 6 months. Brief summary: This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology